A few days ago, my colleague Cory Renauer wrote that there was a big week ahead for Eli Lilly and Company (NYSE: LLY). Cory was right. And we now know the outcomes of several of the big news stories for the drugmaker.Lilly and partner Incyte (NASDAQ: INCY) announced on Monday that an FDA advisory committee recommended approval of the 2 mg dose of baricitinib in treating rheumatoid arthritis, but not the 4 mg dose.